Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 5, 2008, Pages 1162-1168

  Asche, Carl ^a   McAdam Marx, Carrie ^a   Seal, Brian ^b   Crookston, Benjamin ^c   Mullins, C Daniel ^d  

^a UNIVERSITY OF UTAH   (United States)

^b SANOFI   (France)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Antibiotics; Infectious disease; Macrolides; Quinolones

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ADULT; AGE DISTRIBUTION; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; COST OF ILLNESS; DATA BASE; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTPATIENT CARE; RETROSPECTIVE STUDY; SEX RATIO; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HEALTH CARE COSTS; HUMANS; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; QUINOLONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 42149122625     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn073     Document Type: Article

References (19)

1. Banter C, Bavestrello L, Curcio D et al. Acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur). J Chemother 2002; 14 Suppl 4: 1-22.
2. Colice GL, Morley MA, Asche C et al. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004; 125: 2140-5.
3. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
4. Niederman MS, McCombs JS, Unger AN et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37.
5. Doem GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: Data from PROTEKT US 2000-01. J Infect 2004; 48: 56-65.
6. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update. Clin Infect Dis 2004; 39 Suppl 3: S142-50.
7. Arancibia F, Ewig S, Martinez JA et al. Antimicrobial treatment failures in patients with community-acquilred pneumonia: Causes and prognostic implications. Am J Respir Crit Care Med 2000; 162 154-60.
8. Klepser ME, Klepser DG, Ernst EJ et al. Health care resource utilization associated with treatment of penicillin-susceptible and nonsusceptible isolates of Streptococcus pneumoniae. Pharmacotherapy 2003; 23: 349-59.
9. Einarsson S, Kristjansson M, Kristinsson KG et al. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study. Scand J Infect Dis 1998; 30: 253-6.
10. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
11. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347-82.
12. Friis R, Sellers T. Epidemiology for Public Health Practice, 3rd edn. Sudbury, MA: Jones and Bartlett, 2004.
13. Furuno JP, Metlay JP, Harnett JP et al. Population antibiotic susceptibility for Streptococcus pneumoniae and treatment outcomes in common respiratory tract infections. Pharmacoepidemiol Drug Saf 2006; 15: 1-9.
14. Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 2002; 50 Suppl S1: 1-7.
15. Evaluation, Risk Stratification and Current Antimicrobial Treatment Guidelines for Hospital-based Treatment of CAP. Hospital Medicine Consensus Reports 2002, p1-32.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
17. Metlay JP. Update on community-acquired pneumonia: Impact of antibiotic resistance an clinical outcomes. Curr Opin Infect Dis 2002; 15 163-7.
18. Kelley MA, Weber DJ, Gilligan P et al. Breakthrough pneumococcal bacteremia in patients being treated with azlthromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-11.
19. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-64.